| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039728 | BPI LABS | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(10 years from now) | |
| US10004700 | BPI LABS | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(10 years from now) | |
| US9283197 | BPI LABS | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(10 years from now) | |
Epinephrine is owned by Bpi Labs.
Epinephrine contains Epinephrine.
Epinephrine has a total of 3 drug patents out of which 0 drug patents have expired.
Epinephrine was authorised for market use on 04 February, 2022.
Epinephrine is available in solution;intravenous, intraocular, intramuscular, subcutaneous dosage forms.
Epinephrine can be used as emergency treatment of allergic reactions (type 1), including anaphylaxis; a method of treating allergic reaction, anaphylaxis, anaphylactic shock, or combination thereof by an injection of at least one dosage of the injectable liquid pharmaceutical, increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock, induction and maintenance of mydriasis during intraocular surgery.
The generics of Epinephrine are possible to be released after 15 August, 2034.
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 04 February, 2022
Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating...
Dosage: SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE family patents
